KOD vs. EOLS, ABCL, AVBP, OCS, PHVS, SION, COGT, PRTA, CDMO, and AVDL
Should you be buying Kodiak Sciences stock or one of its competitors? The main competitors of Kodiak Sciences include Evolus (EOLS), AbCellera Biologics (ABCL), ArriVent BioPharma (AVBP), Oculis (OCS), Pharvaris (PHVS), Sionna Therapeutics (SION), Cogent Biosciences (COGT), Prothena (PRTA), Avid Bioservices (CDMO), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical products" industry.
Kodiak Sciences vs.
Kodiak Sciences (NASDAQ:KOD) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 45.3% of Kodiak Sciences shares are owned by company insiders. Comparatively, 6.1% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Evolus received 337 more outperform votes than Kodiak Sciences when rated by MarketBeat users. Likewise, 72.80% of users gave Evolus an outperform vote while only 27.54% of users gave Kodiak Sciences an outperform vote.
In the previous week, Evolus had 4 more articles in the media than Kodiak Sciences. MarketBeat recorded 6 mentions for Evolus and 2 mentions for Kodiak Sciences. Evolus' average media sentiment score of 0.89 beat Kodiak Sciences' score of 0.27 indicating that Evolus is being referred to more favorably in the news media.
Kodiak Sciences has a beta of 2.06, suggesting that its share price is 106% more volatile than the S&P 500. Comparatively, Evolus has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500.
Kodiak Sciences currently has a consensus price target of $8.00, indicating a potential upside of 105.13%. Evolus has a consensus price target of $23.67, indicating a potential upside of 65.04%. Given Kodiak Sciences' higher possible upside, equities research analysts plainly believe Kodiak Sciences is more favorable than Evolus.
Kodiak Sciences has a net margin of 0.00% compared to Evolus' net margin of -22.33%. Kodiak Sciences' return on equity of -84.52% beat Evolus' return on equity.
Evolus has higher revenue and earnings than Kodiak Sciences. Evolus is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Evolus beats Kodiak Sciences on 11 of the 17 factors compared between the two stocks.
Get Kodiak Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KOD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kodiak Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:KOD) was last updated on 3/4/2025 by MarketBeat.com Staff
